For anyone who takes care of newborns!! When do we get the baby's blood type? When to check a bilirubin? Is a transcutaneous bilirubin accurate? How do we figure out when to start phototherapy? What about IV fluids? Should we supplement feeds? When do we get a rebound bili? When do we perform an exchange transfusion??!!! So many questions!! The AAP released an updated policy statement in 2022 on how to take care of babies with jaundice above 35 weeks. In this video we cover that paper- and all their Key Action Statements. --------------------------------------------------------------------- Please be sure to give us a like, comment about future topics, and subscribe to this channel to stay up to date on all things NICU! Also, click the notification bell after you subscribe to gain your weekly NICU knowledge as soon as it's loaded! --------------------------------------------------------------------- Dr. Tala is a board-certified neonatologist and has worked in busy level III and IV units for the past 15 years. She has won multiple teaching awards throughout her time as a neonatologist. ---------------------------------------------------------------------- References: Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, Grout RW, Bundy DG, Stark AR, Bogen DL, Holmes AV, Feldman-Winter LB, Bhutani VK, Brown SR, Maradiaga Panayotti GM, Okechukwu K, Rappo PD, Russell TL. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022 Sep 1;150(3):e2022058859. doi: 10.1542/peds.2022-058859. PMID: 35927462.
Sarathy L, Chou JH, Romano-Clarke G, Darci KA, Lerou PH. Bilirubin Measurement and Phototherapy Use After the AAP 2022 Newborn Hyperbilirubinemia Guideline. Pediatrics. 2024 Apr 1;153(4):e2023063323. doi: 10.1542/peds.2023-063323. PMID: 38482582.
Csoma Z, Kemeny L, Olah J. Phototherapy for neonatal jaundice. N Engl J Med. 2008 Jun 5;358(23):2523-4; author reply 2524-5. PMID: 18536103.
---------------------------------------------------------------------------- ***TIMESTAMPS*** 01:58 Prevention of hyperbilirubinemia 04:28 Assessment and Monitoring of hyperbilirubinemia 11:22 Treatment of hyperbilirubinemia 24:57 Post-Discharge follow up ----------------------------------------------------------------------------- *Disclaimer*: This video is intended for educational purposes only and while we strive to give the most accurate information, errors may occur. Subsequently, this video should not be a replacement for medical advice.
AI Generated·May contain errors
Do you ever take care of babies?
And are you a little bit confused
about where we've landed with the jaundice
and the hyperbilirubinemia guidelines
and when we should be starting phototherapy
and which babies we're most concerned about?
Well, you're in the right place.
I'm Dr. Tala and I've been a neonatologist
for over 15 years now.
And today we're going to cover the AAP
or the American Academy of Pediatrics Guidelines,
the most recent update that they put out in 2022
on the management of infants with hyperbilirubinemia.
I'm even wearing yellow so you really remember it.
As a quick reminder,
we did film four videos on jaundice a couple of years ago.
So if you're confused about the difference
between direct and indirect hyperbilirubinemia
or what the difference is between breastfeeding jaundice
and breast milk jaundice
or what is a hemolytic jaundice, hemolytic anemia,
what is a direct coombs,
then go back as a revision and check all of those out
before we go into kind of like
the clinically applicable steps in this video.
So these AAP guidelines cover pretty much everything
that you need to know to be able to take care of babies
above 35 weeks in the NICU.
And just as a reminder, I know you know all of this,
but the main reason that we care
about hyperbilirubinemia or jaundice is to prevent,
yes, conicterus.
We don't want any of these babies getting conicterus.
If you can't remember what that means,
go back and check the previous videos we filmed.
This policy covers four or really five main segments,
but we're gonna cover four.
One, the prevention of hyperbilirubinemia.
Two, it's assessment and monitoring.
Three, treatment.
And four, post-discharge follow-up.
The other great thing about this paper
is it lists 25 key action statements or KAS.
It's the acronym that they use,
which are all statements that we can apply clinically
for our babies, so we'll be covering those as well.
Right, let's start with one,
the prevention of hyperbilirubinemia.
As you all know, this starts
when the mothers are actually pregnant.
We need to know if the babies are set up for hemolysis.
If you remember, the mothers that we worry the most about
are the mothers that are O, type O blood type,
or are H negative.
Also, it's possible that the mother has antibodies
to other red blood cell antigens,
if she had a blood transfusion in the past,
or if she had previous pregnancies.
If you can't remember why, go watch the previous videos.
So the first key action statement is,
if the mother's antibody test is unknown or positive,
which means that she does have little antibodies
floating around her system
that may be attacking antigens on red blood cells,
then we should be getting the baby's blood type
as well as a direct antiglobulin test on the baby,
so basically a COOMS on the baby.
And that will actually check
whether there are antibodies sticking
to the baby's red blood cells and causing them to hemolyze.
So realize this has changed in the past few years.
We used to get baby's blood types on everybody.
Now, we'll only get the baby's blood type and the COOMS
if the mother is Rh negative,
or if the mother has a positive antibody test.
If the mother is O positive, then you have a choice.
You can either send the baby's blood type
and COOMS immediately,
or you can just follow the bilirubin levels
and only end up sending the baby's blood type
if the bilirubin level is getting higher.
The second aspect of prevention
is providing good feeding support.
We know that breastfeeding is highly correlated
with high bilirubin levels.
So it's very important that if mothers are breastfeeding,
that they are provided with adequate support,
whether it's lactation support,
or whether it's encouragement from the postpartum nurses
and everybody else taking care of the mother.
Mothers should be breastfeeding
at least eight times in a 24-hour period,
so on average, Q3 hours.
The second key action statement
covers whether other forms of supplementation
should be used as a way to prevent hyperbilirubinemia.
And in KAS2, they quite clearly say
that oral supplementation with either water
or with a dextrose solution should never be used
in the prevention of hyperbilirubinemia.
Whether you end up supplementing
with donor breast milk or formula
is a decision that can be made
with the team, with the parents.
Now let's talk about the assessment
and the monitoring of hyperbilirubinemia.
What the AAP really emphasize in this section
is that we should identify and be aware of babies
that are especially at high risk
of developing hyperbilirubinemia.
They list the risk factors for developing jaundice
in table one of the paper,
and they're exactly what you would expect.
So prematurity, hemolysis,
need for phototherapy in the first 24 hours of life,
exclusive breastfeeding,
cephalohematomas, LGA, IDM babies,
what we all know.
So they also spend a couple of paragraphs
talking about G6PD deficiency
and the importance of recognizing
whether a baby has it or not.
So remember G6PD deficiency,
and we discussed this in the previous videos,
is a genetic variant of red blood cell metabolism.
So if the infants are lacking that enzyme,
then the red blood cells are more likely to hemolyze.
So obviously it's a non-immune hemolysis.
It is inherited in an excellent manner.
So remember G6PDX, I don't know, that might help.
So obviously it's more common in males.
It's also more common in African, Middle Eastern,
and Southeastern Asian communities.
And about 13% of African American males
have G6PD deficiency.
So obviously a lot of babies in the US as well.
So what the paper really emphasizes
is that if you have a bilirubin that's rising rapidly,
and it looks like it's hemolytic,
so you have a high reticulocyte count,
but it's not immune,
then you should definitely be thinking
about G6PD deficiency, especially if it's a boy.
These babies are at higher risk of developing conicterus.
So obviously a big part of assessment and monitoring
is to actually identify which babies
you have to start phototherapy on.
So that brings us to key action statement number three.
And key action statement three
is that the total serum bilirubin levels
should guide whether you start phototherapy or not.
So whether you start phototherapy or not,
or eventually whether you escalate care,
really depends on three different things.
Number one, the hour specific total serum bilirubin level.
So how many hours old the baby is
when that bilirubin level is checked.
Two, the gestational age of the baby.
And three, whether the baby has
any potential neurotoxic risk factors.
The neurotoxicity risk factors
are all listed out in table two of the paper.
And again, they're exactly
what you would imagine them to be.
So a gestational age of less than 38 weeks,
albumin of less than three grams per deciliter.
And remember, this is because bilirubin
is normally bound to albumin.
So if the albumin is low,
then you'll have more free bilirubin
that can cross the blood brain barrier into the brain.
So then a hemolytic cause is another risk factor.
So isoimmune or for example, G6PD deficiency.
Also sepsis or significant clinical instability
within the last 24 hours.
And that's kind of like a clinician decision.
They didn't really provide a pH
or needing presses or whatever.
But really that's under the understanding
that if the baby is unstable,
then there's more likely to be a breach
in the blood brain barrier
and you're more likely to end up with conicterus
if the baby's unstable.
Now let's cover the visual diagnosis.
As you all probably know,
we're not very good at looking at babies
and seeing how yellow they are
and then estimating the bilirubin levels.
It's not an accurate way of deciding
whether a baby needs phototherapy or not.
The exception to that is if you look at a baby
and the baby doesn't look jaundice at all,
it is incredibly unlikely that that baby
is going to have a high or a critical level of bilirubin.
So again, if you look at a baby and they're not jaundice,
then their bilirubin is probably low.
If you look at a baby and they're jaundice,
then we are awful at actually guessing what that number is.
So it is helpful in that if a baby doesn't look jaundice,
you can feel pretty good about it.
Key action statement four is that every baby in the hospital
should be visually assessed for jaundice
every 12 hours until discharge.
If they look like they're jaundice,
then we should be sending either a serum bili
or at least a transcutaneous bilirubin on that baby.
Which brings us to our next point.
Are transcutaneous bilirubins accurate?
Well, the AAP thinks that they are a reliable
and accurate screening tool to figure out
which babies actually should be getting a serum bilirubin.
And it's good at reducing overall blood draws.
Generally, the serum bilirubin
is about three mgs per deciliter off
from the transcutaneous bilirubin.
It can be one way or another,
but that also really depends on how much melanin
the baby has in its skin.
Also at above 15 mgs per deciliter,
the transcutaneous bilirubin is not accurate
at all after that.
Fifth key action statement is,
is that serum or transcutaneous bilirubin
should be measured at least once
between 24 and 48 hours of life or before discharge.
And straight onto KAS-6,
and that is that a serum bilirubin should be measured
if the transcutaneous bilirubin
is within three milligrams per deciliter
of phototherapy levels,
or obviously if that number is above 15.
KAS-7 is about the rate of rise of the bilirubin.
So if you have two points,
then you can calculate the rate of rise of the bilirubin,
and it can kind of try to help you figure out
whether it's rising really quickly
and it's more likely to be hemolytic or not.
If the rate of rise is above 0.3 mgs per kg per hour
in the first 24 hours,
or above 0.2 mgs per kg per hour after 24 hours,
then this is a high rate of rise
and it's more likely to be hemolytic.
So just based on these two bilirubin points,
it might be reasonable to go ahead
and get the baby's blood type and the coombs and everything.
KAS-8 is if you can't get adequate follow-up
for a baby that's being discharged
to go get their bilirubin checked,
then you should actually delay discharge.
And KAS-9, in infants who are still jaundiced
at two to three weeks of life,
you should also measure a direct bilirubin.
So if the direct bilirubin is above one mg per deciliter,
then this is more suggestive of a liver issue.
So for example, the baby could have biliary atresia,
an inborn error metabolism, a UTI, sepsis,
a whole list of them.
Which brings us to three,
the treatment of hyperbilirubinemia,
which is probably why you're all here.
I won't go into a lot of details about phototherapy.
Just realize that giving phototherapy
chemically alters the bilirubin,
so it's easier for the baby to actually excrete it.
As much as the baby's body should be uncovered
when you're actually giving phototherapy.
And the phototherapy is basically the blue light
with an average wavelength of 475 nanometers.
So between 430 and 490.
So realize that this is regular blue light.
It's not UV light or anything.
So it's not especially dangerous to baby's eyes.
Babies just find it irritating.
That's why we put the goggles on.
The current known risk factors of phototherapy,
according to the AAP,
is that it slightly increases the risk of epilepsy.
However, per the AAP,
if phototherapy is being used
to prevent an exchange transfusion,
then obviously this risk is worth it.
We should be measuring the irradiance level.
So how much phototherapy is actually being given to a baby
on all babies that are receiving it.
And the average should be about
eight to 10 microwatts per centimeter squared.
That's the unit that it's measured in.
When intensive phototherapy is given,
we can give up to 30 microwatts per centimeter squared.
They also discuss the possibility of using sunlight
as a treatment to lower bilirubin levels.
But they kind of go through some of the issues.
And that is that we don't know how much the baby is getting.
We're worried about the baby getting sunburned and stuff.
So using sunlight is not recommended
where we actually have the resources to give phototherapy.
And that's really what these guidelines were used for.
So when do we actually start phototherapy?
Well, key action statement 10
shows when you start phototherapy
based on figures two and three
that are available to everybody.
So for each bilirubin level and gestational age,
you plot out the bilirubin at which hour it is
and figure out whether the baby needs phototherapy or not.
Figure two is for when there are
no neurotoxicity risk factors.
And then you can see there are lines
for different gestational ages.
And again, this is for gestational age at birth.
And it's also dependent on the time the bilirubin was checked.
Again, this is the total serum bilirubin,
not transcutaneous bilirubin.
And you don't subtract the direct bilirubin.
So let's say you have a 39-week infant
who is 24 hours old with a bilirubin of nine.
Do we start phototherapy?
So let's plot that out.
Figure three is for when there is
at least one neurotoxicity risk factor.
So apart from gestational age.
So again, gestational age less than 38 weeks,
albumin less than three, sepsis, hemolysis,
or being critical in at least 24 hours.
Note that infants above 38 weeks
are all grouped together here.
Basically, all these thresholds have increased slightly
from the previous normograms that were released by the AAP.
Probably about two milligrams per deciliter higher.
So we are starting less phototherapy now
than we were a few years ago.
The AAP also notes that it would be acceptable
to start phototherapy at a slightly lower level
just if the baby's about to go home,
just to make sure that the baby
doesn't have to get readmitted.
KAS11, though, is that if a baby does go home
and ends up needing phototherapy,
then home phototherapy can be done
as long as the baby doesn't have
any neurotoxic risk factors.
I'm not gonna go over this more
because it's kind of outside the realm of the NICU.
The importance of feeds are also emphasized
and we all need to make sure
that these babies are feeding very well.
You can stop the phototherapy
while the baby is being breastfed.
So remember, phototherapy kind of starts
an enzymatic reaction,
so the baby doesn't have to be continuously
under the phototherapy for it to work,
but the more time, the better.
IV fluids should only be used
if the baby is actually dehydrated,
so it's like breastfeeding jaundice
and your sodium's 152 or whatever,
or if you're actually escalating care,
so you're getting closer and closer
to need an exchange transfusion,
then yes, you should be starting IV fluids.
12, bilirubin should be checked
once you've started a baby on the phototherapy
at a maximum of 12 hours after starting the phototherapy.
If the baby's bilirubin is high
or there's a rapid rate of rise,
then you should be checking
the bilirubin levels before that.
And again, it should only be the serum bilirubin
that you're checking when a baby is under phototherapy.
When you put them under the phototherapy,
the transcutaneous bilirubin
is the one that's gonna go down the first,
so once you're under phototherapy,
transcutaneous bilirubins are not accurate,
so it needs to be a serum bilirubin.
KAS13, I'm including this
so you don't wonder where number 13 is,
babies who are on home phototherapy
have to have their bilirubins leveled
at least every 24 hours.
Remember, those are babies without neurotoxic risk factors.
KAS14 is important clinically.
What should you be checking
if a baby is placed under phototherapy?
Well, the AAP recommends at least a hematocrit or a CBC,
checking to see if the baby is anemic.
If you're worried about hemolysis,
you can also check a reticular site count.
They don't mention that, but I'm just adding that.
Obviously, you should be checking the baby's blood type
if the mother is O or she had a positive antibody screen,
and then really, you should be trying to figure out
what is actually causing the baby's jaundice,
and should you be worried about hemolysis?
Should you be considering G6PD?
So depending on what the cause is,
then you're more likely to be more or less aggressive.
KAS15 is when you stop the phototherapy,
so you can stop the phototherapy
when it's at least two below,
two mgs per deciliter below the threshold level
for phototherapy for that age.
If the baby has additional risk factors,
so for example, the hyperbilirubinemia is hemolytic,
or phototherapy was started
when the baby was less than 48 hours old,
then you can wait for that bilirubin level
to get further away from the phototherapy level,
so three or four or whatever else you choose.
Let's go on to KAS16.
When do you get a rebound bilirubin?
So to make sure that it hasn't shot up
after you've stopped phototherapy.
So the AAP recommends that you get,
oh, my glasses.
So the AAP recommends that you get a follow-up bilirubin
between 12 and 24 hours after stopping phototherapy,
and if it's hemolytic,
then you can get a bilirubin earlier than that,
so six to 12 hours after stopping phototherapy.
Remember, if the baby's been under phototherapy,
then you have to get a serum bilirubin to check the rebound.
If you're checking a rebound bilirubin
beyond 24 hours after the phototherapy has stopped,
then you can check a transcutaneous bilirubin
because after 24 hours,
kind of all the bilirubin has equilibrated again.
Now let's talk about escalation of care,
which is basically anything that you do beyond phototherapy
to prevent an exchange transfusion.
Again, we've spoken about exchange transfusions as well,
so go back and look at that video
if you want to know anything more about that.
An algorithm is in place for what should occur
when you are escalating care,
and basically, escalation of care should happen
when you are two milligrams per deciliters or less
away from the exchange transfusion levels,
and we'll cover the exchange transfusion level graphs
in a second.
KAS-17 refers to the figures that you have to look at
to determine whether a baby needs
an exchange transfusion or not.
So they're just like the phototherapy graphs,
but these are all obviously a little bit higher,
the numbers, because they're the levels
that you actually have to do an exchange transfusion.
Again, there's one graph for babies
without neurotoxicity risk factors,
and one graph for babies with neurotoxicity risk factors.
So altogether, there's four graphs
that you should be aware of,
two graphs for the phototherapy levels,
and two graphs for the exchange transfusion levels.
So again, when you are looking at the graphs,
you plot out the age-specific serum bilirubin level,
so the hours that the bilirubin was checked at,
on the right gestational age for the baby,
and then you see where it plots out.
If you're within two milligrams per deciliter
of the exchange transfusion level,
then you need to escalate care.
Probably the most important aspect of escalation of care
is making sure that the baby is somewhere
where an exchange transfusion could be done.
So if the baby is still on the floor with their mothers,
then they need to be transferred to the NICU.
If you're in a hospital
where you can't do an exchange transfusion,
then you need to send that baby somewhere where they can.
There are three key action statements
covering the escalation of care.
So 18, K-A-S-18, is that for any babies
that are having escalation of care,
then you should immediately send a STAT,
serum billy, and a direct billy,
a CBC, an albumin level,
chemistries, like checking if the baby's dehydrated
or anything, as well as a type and cross match.
Because if you end up giving blood,
obviously we need to have that blood ready.
K-A-S-19, infants needing escalation of care
need intensive phototherapy, so check the irradiance.
It needs to be closer to that
30 microwatts per centimeter squared number.
So intensive phototherapy, as well as IV hydration,
and there should be a neonatologist on board,
so to admit the baby to the NICU.
K-A-S-20 is that the serum bilirubin level,
when in infants who are requiring escalation of care,
the serum bilirubin level should be measured
every two hours until you are no longer
in the zone of escalation of care.
So until you're at least two or three or four away
from needing the exchange transfusion.
K-A-S-21 is that IVIG or IV immunoglobulin
can be given to babies
with the isoimmune hemolytic type of jaundice.
So obviously the babies that are Coombs positive.
And we made a whole video about this,
so if you want to know more,
then go back and watch these videos.
Generally, we can give between 0.5 and one gram per kilo.
Honestly, by the time I'm giving IVIG,
I pretty much always give the one gram per kilo.
And it needs to be given over two hours.
If you do need to repeat this,
then you can repeat this dose 12 hours later.
And then this is figure four,
which beautifully delineates what you're doing
for the babies when you're escalating care.
And again, you can see it starts very clearly with,
make sure that you are somewhere
where an exchange transfusion can be done.
K-A-S-22 is that an urgent exchange transfusion
should be performed in babies with high bilirubin levels,
even if they're not quite
at the exchange transfusion level,
and any signs of acute bilirubin encephalopathy.
So things like hypotonia, so the baby's a lot stiffer.
Remember, normally when bilirubin levels
are a little bit elevated, like the high teens,
normally babies are a lot sleepier and more tired
and less likely to eat as much.
If they're really going
into the hyper bilirubin encephalopathy stage,
then they can become really stiff
and they can have retrocollis.
So their neck is backwards.
They can have arching.
Also, opisthotonus, I think that's how you pronounce it.
And that's a really bad stage where like,
it's kind of what you can see in adults
with meningitis or something,
where like their whole backs and necks are kind of arching
and very stiff going backwards.
Other signs of bilirubin encephalopathy
are a really high pitched cry
and also the baby developing apneas,
like true central apnea.
And KAS23 is that an urgent exchange transfusion
should be performed once you actually reach
the threshold level for the exchange transfusion,
depending on which graph you're following.
So as you all know, it can take about four hours
at least for the blood to be set up,
getting it ready for the exchange transfusion.
So while you're waiting for that,
you should be checking the bilirubin every two hours.
If the bilirubin level ends up coming down
below the exchange transfusion level,
even if the blood is getting ready,
then you can hold off actually doing
the exchange transfusion.
Just as a reminder, we do the exchange transfusion
by taking out obviously the baby's whole blood
and putting back in red blood cells reconstituted with FFP
or basically with fresh frozen plasma,
all the good proteins that are in blood.
So normally the blood bank has to take red blood cells
and then take FFP and make the hematocrit
of the blood that we're giving about 45%.
So the blood that we're giving
doesn't have white blood cells or platelets.
If you want to know more about this,
go look at the exchange transfusion video.
The AAP also mentions that you can use the bilirubin
divided by the albumin ratio to decide
whether you do want to go forward
with an exchange transfusion or not.
I've actually never used this number
trying to make that decision or not,
but they lay it out very well,
the numbers that you accept
depending on the risk factors for the baby.
So the ratio levels are anywhere between 6.8 to 8,
bilirubin over albumin.
Now let's cover four, the post-discharge follow-up.
And honestly, I think this could be my favorite part
of this entire paper because previously
when we were sending babies home from the hospital
and they had to follow up
with their pediatricians or whatever,
we just kind of went on a hunch
when the babies should be followed up
to check their bilirubin again.
But in this updated policy statement from 2022,
they cover exactly when the baby needs to be followed up
and when the baby needs to be followed up
is dependent from what their discharge bilirubin is
or the bilirubin closest to discharge
and how far away that bilirubin is
from the phototherapy level.
So KAS24 is exactly that,
that the follow-up that the baby needs
will be determined by the last bilirubin
that was checked before the baby went home.
So as you can see from this beautiful figure seven,
if the bilirubin at discharge or right before discharge
is for example, four away from light level,
then the baby needs to follow up in one to two days.
Obviously there are caveats here
that you may want to follow up sooner than that
or later than that, depending on for example,
if the baby's breastfeeding
or if the baby's already lost a little bit of weight,
then obviously you'd want to follow up
a little bit sooner than that.
Also, we need to have policies in place
for how these babies follow up.
And that includes when we send babies home
on weekends or on holidays.
I always think that the Wednesday before Thanksgiving
is absolutely the worst
because Thanksgiving for you non-Americans
falls on a Thursday always.
And so if you're sending a baby home on the Wednesday,
nobody works on Friday of Thanksgiving, Black Friday.
So Thursday, Friday, Saturday, Sunday.
So it's really tough sending babies home
on the Wednesday before Thanksgiving.
And the last CAS, Key Action Statement.
So Key Action Statement 25
is that all families being discharged from the hospital
should receive verbal and written information
about jaundice and the risks of conicterus.
And they should also have the last bilirubin level
that was checked on their baby
and a good plan for follow-up.
Okay, I hope that that helped you all clinically
going through that paper.
I can do that more often if you're all interested in it,
if there's kind of like a big policy statement
or something like that that comes out.
In the meantime, can you tell me where you're watching from?
Like this video.
And again, I really just want to tell you,
thank you so much for being here.